http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1534216-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a0930e40c4e013f10d4116d5fea91913 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18734 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-165 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-165 |
| filingDate | 1977-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1978-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1534216-A |
| titleOfInvention | Production of live mumps virus and vaccine therefrom |
| abstract | 1534216 Mumps vaccine MEDICINSKA AKADAMIA 8 July 1977 28853/77 Heading A5B [Also in Division C6] Mumps vaccine containing attenuated live mumps virus is produced by attenuating Sofia 6 strain of mumps virus by serial passage on a cell culture of cells from the kidneys of newborn guinea pigs (suitably 12 to 25 passages), and then multiplying the attenuated virus by allowing it to replicate on a cell culture of kidney cells of newborn guinea pigs, the culture being infected when it is three to five days old, then collecting the virus, e.g. 2, 4 or 6 days after inoculation of the cell culture, and using it to form a vaccine. The collected virus may be lyophilised, optionally after addition of a stabiliser such as sucrose, human albumin, phosphate and/or gelatin. |
| priorityDate | 1977-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.